GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report
CytoDyn Signs Distribution Deal For Covid-19 Treatment Leronlimab
Sanofi, GSK Close To $624M Covid-19 Vaccine Deal With U.K. - Report
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trial
Regeneron, Sanofi arthritis drug fails COVID-19 study
COVID-19 vaccines to enter late-stage trial by end of July, Fauci says
NIH Director Collins optimistic on COVID-19 vaccine by year end
Tesla to Build Mobile RNA Microfactories for CureVac’s COVID-19 Vaccine
Which drugs and therapies are proven to work, and which ones don't, for COVID-19?
New research from BenovelentAI supports use of Lilly’s Olumiant in COVID-19
Global COVID-19 prevention trial of hydroxychloroquine to resume
Medical cannabis ETFs on cusp of mainstream breakthrough
Bharat Biotech begins trial of COVID-19 vaccine in India as cases mount
Coronavirus: the antibody drugs few people have been discussing – until now
Vaxart Oral COVID-19 Vaccine Joins Trump’s “Warp Speed,” Ramps Up Manufacturing Capacity
Existing drugs can prevent SARS-CoV-2 from hijacking cells
Coronavirus and cancer hijack the same parts in human cells to spread – and our team identified existing cancer drugs that could fight COVID-19
AstraZeneca, Moderna ahead in COVID-19 vaccine race: WHO
Inovio (INO) Stock Is a Winner, but Its Valuation Is Getting Stretched
Children more resilient against coronavirus, study reveals
Molecular Partners hopes for COVID-19 rebound after eye drug failure
COVID-19 drug remdesivir recommended for EU approval
One coronavirus vaccine stock is up 750% this year. Could the rest follow?
3 Biotech Stocks Under $5 With 100%-Plus Upside Potential
Entos Pharmaceuticals announces selection of lead DNA vaccine candidates for COVID-19
3 Under-the-Radar Penny Stocks Gearing up for Gains
Top Analysts See 100%-Plus Upside Potential in These 3 Penny Stocks
Top Analysts Bet on These 3 Penny Stocks; See 100%-Plus Upside Potential
COVID-19 and cancer: can pharma stymie the pandemic’s impact on mortality?
APT Doubles While Other Biotechs Take Off On Rising New Coronavirus Case Numbers